Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     
  • Bitcoin GBP

    51,103.43
    -672.07 (-1.30%)
     
  • CMC Crypto 200

    1,329.45
    -67.08 (-4.80%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Here's Why NuVasive Stock Is Soaring Today

What happened

Shares of NuVasive (NASDAQ: NUVA), a medical device company focused on equipment used during spinal surgery, had risen 13% as of 10:30 a.m. EST on Monday. The double-digit move is attributable to rumors that the company might be an acquisition target.

So what

The Financial Times reported on Friday afternoon that Smith & Nephew (NYSE: SNN) has opened up acquisitions discussions with NuVasive.The report claims that "people familiar with the matter" said the deal would be worth about 2.3 billion pounds, which translates into roughly $3 billion.

Man with glass up to a door
Man with glass up to a door

Image source: Getty Images.

For context, NuVasive's market cap was about $2.5 billion as of Friday.

ADVERTISEMENT

As of the time of this writing, neither company has offered any commentary as to the validity of this report. However, that isn't stopping traders from bidding up the share price today in the hopes that this rumor turns out to be true.

Now what

It is unclear at this time whether an official bid will emerge. However, it is worth noting that on its recent conference call with Wall Street, Smith & Nephew's CEO Namal Nawana stated during his prepared remarks that his team is currently looking at potential acquisitions in markets where there is "a good strategic fit."

While it wouldn't surprise me to find out that these discussions were actually happening, there's no way to know for sure whether an actual deal will materialize. Investors who are interested in buying NuVasive's stock today should do so only if they believe in the long-term potential of the business.

More From The Motley Fool

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends NuVasive. The Motley Fool has a disclosure policy.